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p53 tumoral suppressor gene harbors a functional polymorphism which codes either arginine 
(Arg) or proline (Pro) in the protein p53 of codon 72. Such polymorphism has been associated with 
the development or prognosis of head and neck squamous cell carcinoma (HNSCC). 
Aim: we assessed codon 72 p53 allelic frequencies and genotypes in HNSCC Iranian patients. 
Study design: Case Study. 
Materials and Methods: a total of 132 HNSCC patients and 123 healthy controls were genotyped. 
DNA source was from mononuclear cells of the peripheral blood. DNA amplification was done by 
means of the allele-specific polymerase chain reaction. 
Results: genotypes and allele distribution were not significantly different between patients and 
controls. Moreover, no statistically significant association was found between the 72 and p53 
codon tumor location, gender or age at the time of diagnosis. However, the Pro/Pro genotype was 
significantly increase in stage IV patients (30.8%) when compared to stages I-III of the disease (11.1%) 
(p=0.03), and a significantly higher percentage of patients with the Pro allele had and a risk increase 
in stage IV disease (OR=2.2, 95% CI=1.2-4.2, p=0.01). 
Conclusion: data revealed that the p53 polymorphism do not impact the risk of HNSCC in Iranians, 
nonetheless, it can affect tumor progression to a higher tumor stage.
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INTRODUCTION
Head and neck carcinomas are a group of malignant 
tumors originating form the upper aerodigestive tract inclu-
ding the oral cavity, pharynx, and larynx . More than 90% 
of head and neck carcinomas are squamous cell carcino-
ma, and arise from the epithelial tissues of these regions1.
The incidence of head and neck squamous cell 
carcinoma (HNSCC) shows a wide range of geographical 
variation, with 500 000 new cases worldwide, and is more 
frequent in developing countries. Tobacco and alcohol 
consumption are recognized as the most common environ-
mental carcinogens for HNSCC. However, environmental 
factors can be remarkably influenced by the host genetic 
background1,2. 
The tumor suppressor p53 is a sequence-specific 
DNA-binding transcription factor that acts as the major 
cellular gatekeeper for growth and division. Normal cells 
express a low concentration of this nuclear protein in an 
inactive form, but in response to a wide variety of cellular 
stresses such as DNA damage, hypoxia, or the depletion 
of ribonucleoside triphosphate pools, p53 is activated and 
overexpressed. After activation, p53 mediates either 1) cell 
cycle arrest to allow DNA repair, or 2) apoptosis to remove 
the irreparably damaged cells3. 
The p53 gene, located on chromosome band 
17p13.1, is susceptible to somatic mutation that is estima-
ted to occur in 50% of all human cancers3. The majority 
of these mutations cause dramatic defects in p53 function. 
In contrast, only a small fraction of inherited polymor-
phisms are expected to cause detectable perturbation of 
p53 function3,4. Codon 72 polymorphism in exon 4 is the 
most commonly studied p53 polymorphism that encodes 
either arginine (Arg) or proline (Pro). These variants are 
suggested to alter the structure and function of the p53 
protein. The Pro allele, for instance, induces apoptosis 
with slower kinetics and represses transformation less 
efficiently compared to the Arg allele5. 
Attempts to define the associations of p53 codon 72 
polymorphism with cancer susceptibility or progression 
have yielded inconsistent results in different ethnic back-
grounds and different types of cancer, including HNSCC 
6-11. Because there are no existing data for Iranian patients 
with HNSCC, we investigated the association between 
HNSCC susceptibility and p53 codon 72 polymorphism in 
a case-control study. In addition, the association between 
this polymorphism and gender, tumor location, age and 
disease stage at diagnosis was evaluated. 
PATIENTS AND METHODS
Patients
All participants were informed that blood samples 
would be used for genotyping, and their consent was obtai-
ned. The Ethics Committee of Shiraz University of Medical 
Sciences approved the study. Shiraz University of Medical 
Sciences is a tertiary institution financially supported by the 
Ministry of Health and Medical Education of Iran.  
A total of 132 unrelated patients with HNSCC (97 
men and 35 women; mean age 56.6±14.1 years) were 
recruited from a Shiraz University of Medical Sciences 
hospital (Khalili hospital) in Shiraz, Iran. The diagnosis 
of SCC was confirmed histopathologically for all patients. 
Patients’ characteristics including gender, tumor location, 
age at diagnosis, metastasis, and TNM clinical staging 
were obtained from their medical records. The tumor 
was located in the oral cavity in 52 cases (39.4%), in the 
pharynx in 15 cases (11.4%) and in the larynx in 65 cases 
(49.2%).The mean age at onset of the disease was 55.9±13.1 
years, ranging from 19 to 83 years. Disease stage was 
determined according to the TNM classification. Control 
group comprised
123 healthy volunteers (93 men and 30 women; 
mean age 58.7±12.4 years) residing in the same region 
as patients. Control participants did not have any type of 
cancer or first-degree family history of cancer. The native 
language of all participants was Persian. 
 
DNA preparation and polymerase chain reaction
 
Blood samples were collected in EDTA-containing 
tubes and genomic DNA was extracted from white blood 
cells with salting out method 12. Briefly, whole blood cells 
were first treated with a red blood cell lysis solution (155 
mM NH4CL and 10 mM NaHCO3) and separated from 
white cells by centrifugation. Thereafter white cells were 
lysed in a nuclei lysis buffer (10 mM Tris-HCl, 400 mM 
NaCl and 2 mM Na2EDTA, pH 8.2). The cell lysate was 
digested overnight at 37°C with 10% SDS and a proteina-
se K solution (1 mg proteinase K in 1% SDS and 2 mM 
Na2EDTA). Saturated NaCl (approximately 6M) was then 
added to tubes and shaken vigorously, followed by centri-
fugation. The precipitated protein pellet was left, and the 
supernatant containing the DNA was transferred to another 
tube and mixed with ethanol. The tubes inverted several 
times until the DNA precipitated. The precipitated DNA 
strands were transferred to a 1.5 ml microcentrifuge tube 
containing TE buffer (10 mM Tris-HCl, 0.2 mM Na2EDTA, 
pH 7.5). The DNA was allowed to dissolve 2 hours at 37°C 
before quantitating.
The amplification of DNA was done by an allele-
specific polymerase chain reaction (PCR) method as 
previously described13. Two sets of primers were used to 
detect the Arg and the Pro alleles. The nucleotide sequen-
ces for p53-Arg specific primers were 5’- TCC CCC TTG 
CCG TCC CAA-3’ (forward primer) and 5’-CTG GTG CAG 
GGG CCA CGC-3’ (reverse primer). The primer sequences 
for the amplification of the Pro allele were 5’-GCC AGA 
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GGT TGC TCC CCC-3’ (forward primer), and 5’-CGT GCA 
AGT CAC AGA CTT-3’ (reverse primer).
Each sample was amplified by each set of primers in 
separate tubes containing 0.3 mmol/L dNTPs, 1.5 mmol/L 
MgCl2, 2 U Taq polymerase, and 1× buffer (20 mmol/L 
Tris-HCl, pH 8.4, and 50 mmol/L KCl) (total volume of 
25 μL). Amplification was performed at 35 cycles with a 
touch-down program: denaturation at 94°C for 30 secon-
ds, annealing at 68-62°C for 10 cycles and 62-58°C for the 
remaining 25 cycles, with extension at 72°C for 30 seconds 
in each cycle. PCR products were separated by electro-
phoresis on 2% agarose gel (invitrogen, UK) and stained 
with ethidium bromide. The PCR product was 177 bp for 
the Pro allele and 141 bp for the Arg allele. 
 
Statistical analysis
Genotype frequencies were tested for the Hardy-
Weinberg equilibrium. Fit to the equilibrium was checked 
with the chi-squared test. The data were analyzed with 
SPSS software (version 11.5.0; SPSS, Chicago, IL, USA). 
Differences in the mean age of patients with different 
p53 codon 72 genotypes were calculated with one-way 
analysis of variance (ANOVA). Other analyses were done 
with Pearsons chi-squared test. The differences were con-
sidered statistically significant at a P value less than 0.05. 
Odds ratios (OR) and 95% confidence intervals (CI) were 
calculated by the Mantel- Haenszel method to estimate the 
relative risk associated with alleles.
RESULTS
Genotype frequencies did not differ significantly 
from those expected according to the Hardy-Weinberg 
equilibrium in patients or control participants. The fre-
quencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes 
were 37.1%, 47.7%, and 15.2% in patients with HNSCC, 
and 35.8%, 51.2%, and 13.0% in controls, respectively 
(Table 1). Arg allele frequency was 61.0%, and 61.4% in 
patients and controls, respectively. Pro allele frequency 
was 39.0% in patients and 38.6% in controls. There was 
no statistically significant difference in genotype frequency 
between the patient group and the control group (p=0.82). 
Allele frequencies did not differ significantly between the 
two groups (p=0.92). 
The associations between p53 codon 72 genotypes 
and gender, age at diagnosis, tumor location, metastasis 
and TNM clinical stage are summarized in Table 2. The 
only significant association with the distribution of different 
genotypes was found for tumor stage (p=0.03). The Pro/
Pro genotype was more frequently found in patients with 
stage IV than patients with stage (I-III) disease (p=0.032). 
Although the frequency of this genotype was increased 
in patients with metastasis, the increase did not reach 
statistical significance (p=0.07).
As shown in Table 3, the frequency of the Pro allele 
and the Arg allele were 28 (53.8%) and 24 (46.2) in patients 
with stage IV, and 55 (34.0%) and 107 (66.9) in patients 
with stage I-III disease; this difference was also significant 
(p=0.01), and carriers of the Pro allele had a 2.2-fold higher 
risk of being diagnosed with stage IV (95% CI = 1.2-4.2). 
Table 1. Genotype and allele frequencies of the p53 codon 72 poly-
morphism in 132 patients with head and neck squamous cell carci-
noma  and 123 healthy controls 
 Patients Controls
 n (%) n (%)
Alleles   
Arginine 161 (61.0) 151 (61.4)
Proline 103 (39.0)   95 (38.6)
Genotypes   
Arginine/Arginine 49 (37.1) 44 (35.8)
Arginine/Proline 63 (47.7) 63 (51.2)
Proline/Proline 20 (15.2) 16 (13.0)
No statistically significant difference was found between patients and 
controls in any of the comparisons as calculated with the chi-squared 
test in 2 × 3 or 2 × 2 tables.
Table 2. Association between clinicopathological characteristics of 
132 patients with head and neck squamous cell carcinoma and p53 
codon 72 genotypes
Characteristics
Genotypes
p valuea
Arg/Arg Arg/Pro Pro/Pro
Mean age ±SD 
(years)
57,4±12,5 55±14,7 54,6±9,8 0,63
Gender, n (%) 0,98
Men 36 (37,1) 46 (47,4) 15 (15,5)  
Women 13 (37,1) 17 (48,6) 5 (14,3)  
Tumor location 0,27
Oral cavity 16 (30,8) 30 (57,7) 6 (11,5)  
Pharynx 4 (26,7) 8 (53,3) 3 (20,0)  
Larynx 29 (44,6) 25 (38,5) 11 (16,9)  
Metastasisb 0,07
Negative 37 (38,9) 46 (48,5) 12 (12,6)  
Positive 3 (30,0) 3 (30,0) 4 (40,0)  
Tumor stageb 0,03
I-III 35 (43,2) 37 (45,7) 9 (11,1)  
IV  6 (23,1) 12 (46,1) 8 (30,8)  
aThe p value of the differences in mean age was calculated by the one-
way ANOVA; other p values were calculated with the chi-squared test. 
bThe sum does not equal 100% because of a few missing values.
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DISCUSSION
The p53 tumor suppressor gene is involved in DNA 
repair, the cell cycle, gene transcription, and apoptosis3,4; it 
therefore represents an attractive candidate for attempts to 
explain HNSCC susceptibility and inter-individual variations 
in prognosis. The p53 codon 72 Arg/Pro polymorphism is 
a functional polymorphism whose genotype distribution 
is significantly different among ethnic groups. It has been 
shown that the Pro allele frequency varies from 17% in 
Swedish Saamis to 63% in African Blacks (Nigerians), and 
the proportion of Arg allele carriers is higher in popula-
tions who live farther away from the Earths equator14. The 
association of this polymorphism with cancers, including 
HNSCC, in different ethnic backgrounds is the subject of 
controversy6-11. For instance, the p53 codon 72 polymor-
phism was significantly associated with HNSCC in Italian8, 
but not in Indian9 populations. The high variability of the 
p53 codon 72 Arg/Pro polymorphism among populations 
has frequently been cited to explain differences observed 
in codon 72 in persons with cancer from different ethnic 
backgrounds7. It seems that the correlation of the codon 
72 with cancer should be determined in each population.
We compared the allele and genotype frequencies 
of the p53 codon 72 Arg/Pro polymorphism in HNSCC 
patients and healthy individuals in a southern Iranian 
population. This is, to our knowledge, the first attempt to 
identify the associations of this polymorphism with clini-
cal and prognostic features in an Iranian population. We 
found no significant differences in genotype or allele fre-
quency between patients and healthy control participants. 
However, the Pro/Pro genotype and the Pro allele, asso-
ciated with slower kinetics of apoptosis and less efficient 
suppression of transformation than the Arg allele5, were 
significantly increased in patients with a more advanced 
disease. According to our results, one can argue that the 
effect of the Pro allele may be more pronounced in cancer 
progression than in cancer formation. Although the Pro and 
the Arg alleles have some differences in their abilities for 
apoptosis induction and transformation suppression, they 
do not differ in sequence-specific DNA binding activities5. 
Intriguingly, p53 mutations that are found in 50-55% of all 
human cancers with an important role in cancer formation 
strongly select for p53 proteins with defects for binding to 
DNA3. In agreement with our results, Tu et al. in a Taiwa-
nese population found no association between p53 codon 
72 polymorphism and susceptibility to oral squamous cell 
carcinoma, but found that the p53 codon 72 polymorphism 
was associated with the disease stage, and with overall 
and disease-free survival of irradiated patients10. 
In our study population, distribution of the p53 
codon 72 polymorphism did not differ significantly among 
patients according to the sex, age at diagnosis or tumor 
location. The reported associations of HNSCC characte-
ristics with this polymorphism also vary widely in the 
literature10,11. For example, while the Pro allele was asso-
ciated with an early age of HNSCC onset in non-Hispanic 
whites11, no association was found between p53 codon 
72 polymorphism and the age of the disease onset in 
Taiwanese patients10. The p53 pathway is composed of 
many genes and wide varieties of cellular stress signals 
that activate p53 result in distinct genes being transcribed3. 
Differences in p53 interacting genes, and also differences 
in stress signals among various populations may be other 
explanations for the diverse results.
CONCLUSION
In conclusion, we detected a significant positive 
association between the Pro allele of the p53 codon 72 
and tumor stage, an important prognostic factor in HNSCC. 
However, we found no significant association between 
this polymorphism and risk of HNSCC in Iranian patients. 
More data from a larger number of patients are needed 
to determine the possible minor association between the 
p53 codon 72 Arg/Pro polymorphism and HNSCC risk.  
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